ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 18 Issue : 5 Year: 2017
Current Issue Archive Popular Article Ahead of Print

   
Quick Search





 
The Anatolian Journal of Cardiology The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction [Anatol J Cardiol]
Anatol J Cardiol. 2011; 11(7): 613-617 | DOI: 10.5152/akd.2011.164  

The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction

Eyüp Avcı1, Murat Yeşil2, Serdar Bayata3, Nursen Postacı4, Erdinç Arıkan4, Mustafa Cirit5
1Atatürk Eğitim Hastanesi, 1. Kardiyoloji Kliniği, İzmir, Türkiye
2Sağlık Bakanlığı İzmir Atatürk Eğitim ve Araştırma Hastanesi, 1. Kardiyoloji Kliniği, İzmir, Türkiye
3Department of Cardiology, İzmir Atatürk Training and Research Hospital, İzmir, Turkey
4Clinic of Cardiology Atatürk Education and Research Hospital, İzmir-Turkey
5Clinic of Nephrology, Atatürk Training and Research Hospital, İzmir-Turkey

Objective: This prospective study was designed to evaluate the potential protective effect of nebivolol compared with metoprolol on the development of contrast-induced nephropathy (CIN) following coronary angiography in patients with renal dysfunction. Methods: Ninety patients with stable coronary angina pectoris with renal insufficiency (creatinine value ≥ 1.2 mg/dl) were included for this prospective study. Patients were divided into two groups. Patients in group 1 (n=55) received oral administration of nebivolol 5 mg/daily for coronary artery disease and/or hypertension. Group 2 consisted of 35 patients who received metoprolol 50 mg/daily for the same indications. All patients were hydrated with 0.9% NaCl at a rate of 1 mL/kg/hr for 12 hours before and 24 hours after the procedure. Patients were also given N-acetylcysteine (NAC) 600 mg twice a day, beginning 24 hours before and continuing 48 hours after the procedure. All patients underwent routine coronary angiography. Serum creatinine was assessed just before, immediately after and 48 hours after the procedure. CIN was defined as an increase in serum creatinine concentration of ≥25% within 48 hours after the procedure compared to the patient’s baseline value. Tests for significance between groups were conducted using the independent sample t-test for continuous variables and Chi-square test for categorical variables. Results: Baseline serum creatinine levels were statistically comparable in two groups. Following angiography, serum creatinine levels increased in both groups. Post-angiographic creatinine levels were not statistically different in the nebivolol and the metoprolol groups. Contrast induced nephropathy developed in 13 patients (24%) of the nebivolol group and in 12 patients (33%) of the metoprolol group. The incidence of CIN was statistically significantly lower in the nebivolol group comparing with the metoprolol group (p=0.03). Conclusion: The use of oral nebivolol for one week at a dose of 5 mg per day may decrease the incidence of contrast-induced nephropathy in patients who underwent coronary angiography with renal dysfunction. The small numbers of this study do not allow to draw final conclusion on the use of nebivolol in the prevention of CIN. Therefore, larger studies may be necessary to address the definite role of nebivolol in this setting.

Keywords: Contrast-induced nephropathy, beta-blocker, nebivolol, renal dysfunction


Eyüp Avcı, Murat Yeşil, Serdar Bayata, Nursen Postacı, Erdinç Arıkan, Mustafa Cirit. The role of nebivolol in the prevention of contrast-induced nephropathy in patients with renal dysfunction. Anatol J Cardiol. 2011; 11(7): 613-617


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share


Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright © 2016 Turkish Society of Cardiology